Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease

Thrombosis Research

Volumn 124, Issue 3, 2009, Pages 259-261

  Vaidyula, Vijender Reddy ^a   Criner, Gerard J ^a   Grabianowski, Carla ^a   Rao, A Koneti ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic Obstructive Pulmonary Disease; Factor VII; Factor VIII; Thrombotic Disease; Tissue Factor

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; PROCOAGULANT; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ARTICLE; BLOOD CLOTTING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBIN TIME;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 67649742571     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.12.030     Document Type: Article

References (22)

1. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 343 4 (2000) 269-280
2. Sin D.D. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2 (2005) 8-11
3. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 16 (2005) 1685-1695
4. Tillie-Leblond I., Marquette C.H., Perez T., Scherpereel A., Zanetti C., Tonnel A.B., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 144 6 (2006) 390-396
5. Curkendall S.M., DeLuise C., Jones J.K., Lanes S., Stang M.R., Goehring Jr. E., et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16 1 (2006) 63-70
6. Rauch U., and Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 10 4 (2000) 139-143
7. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24 6 (2004) 1015-1022
8. Bokarewa M.I., Morrissey J.H., and Tarkowski A. Tissue factor as a proinflammatory agent. Arthritis Res 4 3 (2002) 190-195
9. Giesen P.L., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J.T., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 96 5 (1999) 2311-2315
10. Key N.S., Slungaard A., Dandelet L., Nelson S.C., Moertel C., Styles L.A., et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 91 11 (1998) 4216-4223
11. Chou J., Mackman N., Merrill-Skoloff G., Pedersen B., Furie B.C., and Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104 10 (2004) 3190-3197
12. Vaidyula V.R., Rao A.K., Mozzoli M., Homko C., Cheung P., and Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 55 1 (2006) 202-208
13. Tutar E., Ozcan M., Kilickap M., Gulec S., Aras O., Pamir G., et al. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 108 13 (2003) 1581-1584
14. Sambola A., Osende J., Hathcock J., Degen M., Nemerson Y., Fuster V., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 7 (2003) 973-977
15. Asakura H., Kamikubo Y., Goto A., Shiratori Y., Yamazaki M., Jokaji H., et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 80 3 (1995) 217-224
16. Abdel-Hafiz E., Vaidyula V.R., Bagga S., London F.S., Boden G., and Rao A.K. Elevated whole blood tissue factor procoagulant activity in diabetes mellitus. Vitamin E inhibits glucose induced tissue factor activity in vitro. Blood 100 (2002) 496a
17. Boden G., Vaidyula V.R., Homko C., Cheung P., and Rao A.K. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 92 11 (2007) 4352-4358
18. Himber J., Wohlgensinger C., Roux S., Damico L.A., Fallon J.T., Kirchhofer D., et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 1 5 (2003) 889-895
19. Kamikura Y., Wada H., Nobori T., Kobayashi T., Sase T., Nishikawa M., et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. Thromb Res 116 4 (2005) 307-312
20. Arnaud E., Barbalat V., Nicaud V., Cambien F., Evans A., Morrison C., et al. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol 20 3 (2000) 892-898
21. Morrissey J.H., and Mutch N.J. Tissue factor structure and function. In: Colman R.W., Marder V.J., Clowes A.W., George J.N., and Goldhaber S.Z. (Eds). Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2006), Lippincott Williams & Wilkins, Philadelphia
22. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 7 (2004) 574-580